Microaspiration in Pulmonary Fibrosis (ROMI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01150591|
Recruitment Status : Completed
First Posted : June 25, 2010
Last Update Posted : December 2, 2015
Hypothesis 1: Microaspiration, as diagnosed by bronchoalveolar lavage (BAL) pepsin, is common in patients with IPF.
Hypothesis 2a: Baseline clinical variables and co-morbid conditions are risk factors for microaspiration in patients with IPF.
Hypothesis 2b: Baseline biological variables reflecting alveolar epithelial injury and inflammation are markers of microaspiration in IPF.
Hypothesis 3a: Microaspiration will lead to a more rapid rate of decline in pulmonary function.
Hypothesis 3b: Microaspiration will lead to higher rates of urgent medical care use (i.e. unscheduled clinic visit, emergency room visit, or hospitalization).
|Condition or disease|
|Idiopathic Pulmonary Fibrosis|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||The Role of Microaspiration in Idiopathic Pulmonary Fibrosis|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||June 2015|
- BAL pepsin level [ Time Frame: Cross sectional ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01150591
|United States, California|
|University of California San Francisco|
|San Francisco, California, United States, 94610|